Physician profile
Melissa Velez
NPI 1639392855
$67,605.45
in general payments reported to CMS, 2019-2025
38 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,468 · 2022: $14K · 2023: $8,116 · 2024: $26K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $9,855 · Travel and Lodging: $5,873 · Consulting Fee: $2,070 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,367.03 |
| Food and Beverage | $9,854.61 |
| Travel and Lodging | $5,873.09 |
| Consulting Fee | $2,070.00 |
| Education | $174.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $56,297.09 | 2021-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $2,754.73 | 2021-2025 | Tysabri, Vumerity, Leqembi |
| Abbott Laboratories | $1,497.73 | 2022-2025 | Infinity |
| Tg Therapeutics, INC. | $994.39 | 2024-2025 | |
| Celgene Corporation | $809.12 | 2021-2025 | Zeposia |
| Mdd US Operations, LLC | $753.62 | 2021-2025 | Gocovri, Gocovri |
| Abbvie INC. | $697.79 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $458.16 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $422.29 | 2022-2025 | Amvuttra |
| Eisai INC. | $362.32 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $350.97 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Alexion Pharmaceuticals, INC. | $328.15 | 2022-2025 | Ultomiris |
| Grifols USA, LLC | $182.84 | 2022-2025 | Gamunex-C |
| Argenx US, INC. | $169.36 | 2024-2025 | Vyvgart Hytrulo |
| Genentech USA, INC. | $131.84 | 2022-2024 | Ocrevus, Ocrevus Zunovo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $130.63 | 2023-2025 | Daybue, Nuplazid |
| Merz Pharmaceuticals, LLC | $127.79 | 2022-2025 | Xeomin |
| Otsuka America Pharmaceutical, INC. | $125.33 | 2024-2025 | Rexulti |
| Lundbeck LLC | $120.63 | 2022-2025 | Vyepti |
| Genzyme Corporation | $118.48 | 2021-2025 | |
| Sk Life Science, INC. | $110.12 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $97.70 | 2022-2024 | Keveyis |
| Amgen INC. | $95.97 | 2025 | Uplizna |
| Pfizer INC. | $71.20 | 2023-2025 | |
| Kyowa Kirin, INC. | $47.99 | 2024 | Nourianz |
| Ucb, INC. | $44.72 | 2022-2025 | Rystiggo |
| Allergan, INC. | $33.74 | 2021-2022 | |
| Boston Scientific Corporation | $30.38 | 2021 | |
| Neurelis, INC. | $29.00 | 2023 | Valtoco |
| Neurocrine Biosciences, INC. | $28.62 | 2024 | Ingrezza |
| Life Molecular Imaging Ltd | $25.36 | 2025 | Neuraceq |
| Csl Behring | $24.94 | 2025 | Hizentra |
| Springworks Therapeutics, INC. | $24.58 | 2025 | Gomekli |
| Lilly USA, LLC | $22.61 | 2025 | Kisunla |
| Acera Surgical, INC. | $22.58 | 2025 | Restrata Wound Matrix |
| Avion Pharmaceuticals | $22.50 | 2023 | Dhivy |
| Cycle Pharmaceuticals INC | $22.03 | 2025 | Tascenso Odt, Bafiertam |
| Ipsen Biopharmaceuticals, INC | $18.15 | 2025 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.